ArticleACS omega2025
Development of Optimized
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oregano essential oil (OEO), rich in carvacrol and thymol, has bioactive properties but is prone to degradation due to its volatile nature. Nanoencapsulation by complex coacervation, using chitosan (CHI) and gum arabic acid (GA), emerges as an alternative to increase its stability in food matrices. This study investigated the influence of the CHI/GA mass ratio on the formation of OEO-containing nanocapsules and quantified the encapsulated carvacrol using validated GC-MS. A Box-Behnken experimental design optimized the OEO concentration, CHI/GA ratio, and amount of Tween 80. Physicochemical properties such as the diameter, PdI, and zeta potential were evaluated. Morphology was analyzed by SEM and AFM, and thermal stability by TGA and DSC. Stability was monitored for 120 days at 4 °C, 25 °C, and 40 °C. The optimized formulation (470 mg of OEO, 659 mg of CHI/GA 1:5, and 13 mg of Tween) resulted in nanocapsules with a diameter of 323 ± 22 nm, a PdI of 0.20 ± 0.02, and a zeta potential of +15.8 ± 0.8 mV. FTIR analysis confirmed electrostatic interactions between CHI and GA. GC-MS identified 24 constituents in the OEO, with carvacrol as the main compound (78.8%). The validated method showed an
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.